Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017

PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of...
July 14, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency

PHILADELPHIA, July 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) ("Hemispherx" or the “Company") today announced key elements of its strategic growth plan as well as additional...
February 22, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value

PHILADELPHIA, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has announced that the Board of Directors has made several changes to its...
September 28, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations

PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
August 31, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Photo Release -- Hemispherx Biopharma Fully Aligns Executive Bonus Programs to Accelerate Product Revenue Opportunities and Market Entry

NEW BRUNSWICK, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing and Research and Development (R&D)...
August 11, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Expands Its Collaboration With Emerge Health for the Commercialization of Alferon in Australia and New Zealand

PHILADELPHIA, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
July 14, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine

PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance to develop multiple projects with Bioclones...
July 08, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania

PHILADELPHIA, July 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced execution of an agreement to seek South African government approval...
May 21, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets

PHILADELPHIA, May 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced the preliminary stage agreement required to manufacture...